Results 71 to 80 of about 21,698 (162)

Analysis of the impact of national centralized volume-based procurement drug policy on the market dynamics of tuberculosis drugs. [PDF]

BMC Health Serv Res
Yang J, Yu X, Yao Y, Zhao W, Chen Y, Wang Z, Xu M.   +6 more
europepmc   +1 more source

Therapeutic drug monitoring of first-line anti-tuberculosis drugs: impact of dose modification on plasma drug concentrations in pulmonary and extrapulmonary tuberculosis. [PDF]

J Clin Tuberc Other Mycobact Dis
Alavandar A.
europepmc   +1 more source

Epidemiology of extrapulmonary tuberculosis, Alameda County, California, 2010-2021. [PDF]

J Clin Tuberc Other Mycobact Dis
Nasir S, Marusinec R, Chitnis AS, Jaganath D.   +3 more
europepmc   +1 more source

Saliva as an Alternative Matrix for Pharmacokinetic Research and Therapeutic Drug Monitoring of the Antituberculosis Drug Pyrazinamide. [PDF]

Antibiotics (Basel)
Ndaro AJ, Semvua HH, Mtabho CM, Heijens CAW, Te Brake LHM, Kibiki GS, Aarnoutse RE.   +6 more
europepmc   +1 more source

Acetylator status-guided rapid reintroduction of isoniazid in tuberculosis patients with drug-induced hepatotoxicity. [PDF]

J Clin Tuberc Other Mycobact Dis
van Arkel C, Stemkens R, Magis-Escurra C, Hoefsloot W, Carpaij N, van Ingen J, van Crevel R, van Laarhoven A, Aarnoutse R.   +8 more
europepmc   +1 more source

Utility of Patch Testing, LTT, and HLA Genotyping in Identifying Culprit Drugs and Diagnosing Multiple Drug Hypersensitivity in Definite DRESS: A 10-Year Cohort Study. [PDF]

Clin Transl Allergy
Ünal D, Yeğit OO, Demir S, Erden B, Korkmaz P, Oğuz FS, Çınar ÇK, Temurhan S, Karabacak DE, Toprak ID, Kılınç Z, Yordam MS, Kahveci N, İğde MH, Kamacı ŞÇ, Aslan AF, Sezgin ME, Kaya E, Bölek L, Coşkun R, Olgaç M, Öztop N, Gelincik A.   +22 more
europepmc   +1 more source

Implementing shorter all-oral treatment durations for multidrug-resistant tuberculosis in the UK: from concept to application. [PDF]

BMJ Open Respir Res
Chavda A, Gilchrist M, Capstick T, Chen C, Kon OM.   +4 more
europepmc   +1 more source

Pharmacokinetic modelling as a tool to assess TB treatment adherence: application to the REMEMBER study. [PDF]

IJTLD Open
Abdelgawad N, Chirehwa M, McIlleron H, Kanyama C, Mwelase N, Naidoo A, Kumwenda J, Nyirenda M, Samaneka WP, Lama JR, Mohapi L, Mave V, Veloso VG, Valencia J, Gupta A, Hosseinipour MC, Scarsi K, Denti P.   +17 more
europepmc   +1 more source

A scoping review of interventions in childhood tuberculosis prevention and treatment. [PDF]

Public Health Pract (Oxf)
Rahaman MZ, Alam T, Nahar SS, Nahrin R, Bushra IJ, Ahmed S, Banu S, Shahrin L.   +7 more
europepmc   +1 more source

Correction: Population pharmacokinetics model of pyrazinamide to optimize tuberculosis treatment: An interethnic cohort study of diabetes mellitus effect on drug exposure. [PDF]

PLoS One
Jayanti RP, Cho YS, Soedarsono S, Kim HJ, Kang J, Kim J, Oh JY, Kang BH, Ha JH, Kim JW, Mertaniasih NM, Kusmiati T, Permatasari A, Yuliwulandari R, Kim R, Seong HJ, Ghim JL, Kim DH, Shin JG, cPMTb.   +19 more
europepmc   +1 more source